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The CAP-Gly Domain of CYLD Associates
with the Proline-Rich Sequence in NEMO/IKK
chemical shift mapping revealed that the peptide bind-
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Familial cylindromatosis (turban tumor syndrome) is an1RIKEN Genomic Sciences Center
autosomal dominant predisposition to multiple neoplasms1-7-22 Suehiro-cho
of the skin appendages. The tumors, called cylindromasTsurumi, Yokohama 230-0045
because of their characteristic microscopic architec-Japan
ture, arise mainly in hairy areas of the body, especially2 Graduate School of Integrated Science
on the head and neck. The gene responsible for theYokohama City University
disease (cyld) is located on chromosome 16q12-131-7-26 Suehiro-cho
(Biggs et al., 1995, 1996; Thomson et al., 1999; TakahashiTsurumi, Yokohama 230-0045
et al., 2000). The cyld gene product (CYLD) comprisesJapan
956 amino acid residues and contains a ubiquitin car-3 RIKEN Harima Institute at SPring-8
boxyl-terminal hydrolase (UCH) catalytic domain (Big-1-1-1 Kouto
nell et al., 2000) (Figure 1A). Recently, the participationMikazuki-cho, Sayo, Hyogo 679-5148
of CYLD in the NF-B signaling pathway was reportedJapan
(Brummelkamp et al., 2003; Kovalenko et al., 2003;4 Facility for Genome Structure Analysis
Trompouki et al., 2003).Kazusa DNA Research Institute
NF-B plays prominent roles in the inducible expres-2-6-7 Kazusakamatari
sion of genes involved in diverse biological processes,Kisarazu, Chiba 292-0818
including development, immune and inflammatory re-Japan
sponses, cell growth and death, stress responses, and5 RIKEN Research Center for Allergy
oncogenesis (for review, see Ghosh and Karin, 2002).and Immunology
Cell stimulation with a variety of agonists triggers the1-7-22 Suehiro-cho
signal pathways that ultimately result in the activationTsurumi, Yokohama 230-0045
of IB kinase (IKK). It appears that CYLD directly inter-Japan
acts with the carboxyl-terminal region of the NF-B es-6 Department of Biophysics and Biochemistry
sential modulator (NEMO/IKK) and regulates the kinaseGraduate School of Science
activity of IKK through the deubiquitination of tumor necro-The University of Tokyo
sis factor (TNF) receptor-associated factors (TRAF). Six7-3-1 Hongo
members of the TRAF family have been identified, andBunkyo-ku, Tokyo 110-0033
their proteins share a carboxyl terminal homology regionJapan
termed the TRAF (or MATH) domain (Uren and Vaux,
1996). TRAF proteins act as cytoplasmic adaptors that
directly interact with the intracellular domains of cell
Summary surface receptors (for review, see Arch et al., 1998; Brad-
ley and Pober, 2001). The recognition of diverse recep-
CYLD was originally identified as the human familial tors by TRAF was revealed by structural studies (Park
cylindromatosis tumor suppressor. Recently, it was et al., 1999; Ye et al., 1999; McWhirter et al., 1999; Ni et
reported that CYLD directly interacts with NEMO/IKK al., 2000). A TRAF2 consensus binding sequence exists
and TRAF2 in the NF-B signaling pathway. The two within CYLD (457-PVQES-461), and the interaction is
proteins bind to a region of CYLD that contains a Cys- lost by mutating S461 of CYLD, indicating that the region
box motif and the third cytoskeleton-associated pro- is the TRAF2 binding site (Kovalenko et al., 2003). The
tein-glycine conserved (CAP-Gly) domain. Here we NF-B-inducing activity of TRAFs depends on their
report that the third CAP-Gly domain of CYLD specifi- RING finger-dependent ubiquitin ligase activity and au-
cally interacts with one of the two proline-rich se- toubiquitination (Wang et al., 2001; Shi and Kehrl, 2003).
quences of NEMO/IKK. The tertiary structure of the The autoubiquitination requires the activity of the ubiqui-
CAP-Gly domain shares the five-stranded  sheet to- tin-conjugating enzyme Ubc13, which facilitates polyu-
pology with the SH3 domain, which is well known as a biquitination formation through K63, although this ubi-
proline-rich sequence-recognition domain. However, quitination does not mediate degradation, in contrast
to K48 polyubiquitination (Deng et al., 2000).
NEMO/IKK is a regulatory subunit of the IKK complex*Correspondence: yokoyama@biochem.s.u-tokyo.ac.jp
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Figure 1. The Third CAP-Gly Domain in Hu-
man CYLD Protein Binds NEMO/IKK
(A) Domain structure of the human CYLD pro-
tein. CYLD contains three CAP-Gly domains,
two proline-rich regions (indicated as P), and
one ubiquitin carboxyl-terminal hydrolase
type 2 catalytic domain (UCH type 2).
(B) NEMO/IKK and the third CAP-Gly domain
of CYLD were coprecipitated in coexpressed
cell extracts. FLAG-tagged CYLD constructs
and c-Myc-tagged NEMO/IKK were coex-
pressed in HeLa cells. The extracts were im-
munoprecipitated (IP) with anti-Flag affinity
gel (left) or anti-c-myc antibody (right) and
immunoblotted (IB) with anti-NEMO/IKK
(right) or anti-Flag (right) antibodies.
(Rothwarf et al., 1998; Yamaoka et al., 1998). NEMO/ three-dimensional structure of the third CAP-Gly domain
of CYLD by NMR spectroscopy. Based on chemical shiftIKK contains several putative motifs: the amino-termi-
nal large coiled-coil domain, which is required for bind- perturbation data, we provide evidence that the CAP-
Gly domain specifically interacts with one of the twoing to IKK, and the carboxyl-terminal domain, which
comprises three subdomains including a coiled coil, a proline-rich sequences of NEMO/IKK.
leucine zipper, and a zinc finger. Genetic studies sug-
gested that NEMO/IKK is necessary for the activation Results
of IKK within the NF-B signaling pathway by diverse
stimuli. The complete loss of NF-B activity was shown The Third CAP-Gly Domain Is Needed
by various stimuli in mouse knockout experiments (Ru- for NEMO/IKK Binding
dolph et al., 2000; Makris et al., 2000; Schmidt-Supprian NEMO/IKK binds to the region encompassing residues
et al., 2000). Moreover, two types of human disorders 470–684 in CYLD (Kovalenko et al., 2003), which con-
have been genetically linked to mutations in the NEMO/ tains the third CAP-Gly domain and the Cys-box motif.
IKK gene. Nonsense mutations in the NEMO/IKK gene Structurally, the Cys-box belongs to the UCH catalytic
are associated with incontinentia pigmenti (Smahi et al., domain (Hu et al., 2002), and therefore we thought that
2000), whereas point mutations in the encoded car- the CAP-Gly domain might be a NEMO/IKK binding
boxyl-terminal zinc finger domain, affecting only a sub- site. In order to evaluate this hypothesis, the construct
set of NF-B activation pathways, are found in patients (residues 464–554) containing only the CAP-Gly domain
with anhidrotic ectodermal dysplasia in conjugation with was coexpressed with full-length NEMO/IKK in cul-
immunodeficiency syndromes (Doffinger et al., 2001; tured cells, and their extracts were coimmunopreci-
Jain et al., 2001). TNF- stimulates the K6-linked ubiqui- pitated (Figure 1B). The CAP-Gly domain was copreci-
tination of NEMO/IKK, which is mediated by c-IAP1, pitated with NEMO/IKK and vice versa. Moreover,
an inhibitor of apoptosis protein (Tang et al., 2003). On
the other hand, B cell lymphoma/leukemia 10 (Bcl10)
targets NEMO/IKK for K63-linked ubiquitination at
Table 1. Structural Statistics for the CAP-Gly Domain—20
K399, which is located in the carboxyl-terminal zinc fin- Structures
ger of NEMO/IKK (Zhou et al., 2004). NEMO/IKK is
NOE distance constraintsalso modified by the small ubiquitin-like modifier (SUMO),
Intraresidue 839
and its subsequent ubiquitination mediates NF-B acti- Sequential 585
vation by relocalizing NEMO/IKK from the nucleus to Medium-range 333
the cytoplasm (Huang et al., 2003). Long-range 910
Dihedral angle constraintsCYLD contains three CAP-Gly domains in its amino
Main chain (φ/) 90terminus (Bignell et al., 2000). The CAP-Gly domain con-
Side chain (1) 30sists of about 70 amino acid residues, with the charac-
Root-mean-square deviation from idealized covalent geometry
teristically conserved hydrophobic and glycine residues. Bonds (A˚) 0.0006  0.00005
This domain exists in several microtubule (MT) binding Angles () 0.251  0.0012
proteins, such as the cytoplasmic linker protein CLIP- Impropers () 0.085  0.0012
Root-mean-square deviation from experimental restraints170 (Restin), p150glued (Dynactin 1), and the tubulin
NOE (A˚) 0.0014  0.0005folding cofactors B and E (Riehemann and Sorg, 1993).
Dihedrals () 0.13  0.012It appears that the domains themselves are responsible
Ramachandran plot (%)
for their colocalization with MT (Pierre et al., 1994; Feier- Most favored region 74.1
bach et al., 1999; Scheel et al., 1999; Radcliffe and Toda., Additionally allowed region 25.5
2000). Although it is not known whether CYLD colocal- Generously allowed region 0.1
Disallowed region 0.3izes with MT and whether the CAP-Gly domains of CYLD
Root-mean-square deviation to the mean structure (A˚)can bind to MT, we considered that the domains could
Backbone (residues 473–548) 0.40  0.06be responsible for protein-protein interactions, includ-
Nonhydrogen atoms (residues 473–548) 0.90  0.08
ing MT binding. In this study, we have determined the
CAP-Gly Binds to a Proline-Rich Sequence
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Figure 2. The CAP-Gly Domain Structure
(A) Best-fit superpositions of the final 20 simulated annealing structures of the CAP-Gly domain. Only the main chains of residues 473–548
are presented.
(B) Two major hydrophobic cores. Hydrophobic and aromatic side chains are presented in green.
(C) The structures (represented by ribbon models and topology diagrams) of the CAP-Gly and the SH3 domain of c-CRK (PDB code: 1CKA)
are compared. The five common  strands are numbered.
Structure
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Figure 3. The CAP-Gly Domain Specifically Interacts with One of the Two Proline-Rich Sequences of NEMO/IKK
(A) Domain structure of NEMO/IKK. The coiled-coil (CC), leucine-zipper (LZ), and zinc finger (ZF) motifs are presented.
(B) Primary sequence of the carboxyl terminus of human NEMO/IKK. The CCHC-type zinc finger motif is shaded, and the two peptide
sequences used for the perturbation study are underlined.
(C) Comparison of the 1H, 15N correlation spectra of the CAP-Gly domain in the absence (black) and presence of 10 (red) molar equivalents
of peptide2. The crosspeaks that appeared upon peptide addition are indicated by arrowheads. The boxed region is magnified and presented
in (D).
(D) Detailed comparison of the 1H, 15N correlation spectra of the CAP-Gly domain in the absence (black) and presence of 5 (green) or 10 (red)
molar equivalents of peptide1 (upper panel) or peptide2 (lower panel).
endogenous NEMO was coprecipitated with the CAP- L536, and V538, which make a barrel-like fold (Figure
2B, right).Gly domain (Figure 1B, left panel, lanes 3), strengthening
The crystal structure of the CAP-Gly domain fromthe idea that the CAP-Gly domain contains the structural
nematode hypothetical protein was reported (Li et al.,elements needed for NEMO/IKK binding.
2002), and its folding topology is quite similar. One sig-
nificant difference is the existence of an additional 
The Solution Structure of the CAP-Gly Domain helix within the amino-terminal region. No significant
The solution structure of the third CAP-Gly domain was nonsequential interresidue NOEs were observed in this
calculated (Table 1). The structure of residues 473–548 region when the longer construct was analyzed (resi-
is well defined (Figure 2A) and consists of a five-stranded dues 414–558; data not shown), indicating that it is un-
(residues 479–481, 489–496, 505–509, 536–539, and structured.
543–545) antiparallel sheet with an inserted antiparallel The folding topology of the CAP-Gly domain resem-
 sheet-like loop (residues 511–534). There are two sig- bles that of the src homology 3 (SH3) domain (Figure
nificant hydrophobic cores in the domain. One consists 2C). The two proteins share similar topologies of the
of five aromatic side chains (W494, Y521, F522, F528, five  strands. The SH3 domain is well known as a pro-
and F537) between the  sheet and the  sheet-like loop line-rich peptide binding motif, and its RT loop is in-
volved in ligand recognition (for review, see Macias et(Figure 2B, left). The other consists of V482, F488, L510,
CAP-Gly Binds to a Proline-Rich Sequence
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Figure 4. The 15N-NOESY Spectra of the Rep-
resentative Amide Protons
The NOE crosspeaks were compared in the
absence (left) and presence (right) of the li-
gand. The peaks that appeared upon ligand
addition are indicated by arrows.
al., 2002). Although the inserted positions of the long peptide, the crosspeak of E481 was broad, and further-
more, the crosspeaks of V482, K483, and E484, whichloops in the primary sequence are distinct between the
SH3 and CAP-Gly domains, they are close in the tertiary are the turn conformation between  strands 1 and 2,
were too broad to be observed (assuming exchangestructure. In addition, the shape of the ligand binding
surface in the SH3 domain is somewhat similar to the broadening). Actually, the numbers of NOEs are smaller
than those of other residues, and therefore the turncorresponding surface in the CAP-Gly domain. Thus,
the CAP-Gly domain may also interact with a proline- region is relatively not well ordered (Figure 2A). However,
the peak of E481 gradually became sharper, and unas-rich ligand.
signed peaks (indicated by arrowheads in Figures 3C
and 3D) appeared with the addition of the peptide. TheseThe CAP-Gly Domain Interacts with One
of the Two Proline-Rich Sequences findings suggested that the conformation of the turn is
originally multiple but becomes more restricted uponof NEMO/IKK
The carboxyl-terminal 39 amino acid residues in NEMO/ ligand binding. Similar phenomena were observed by
decreasing the temperature of the ligand-free sampleIKK interact with CYLD (Kovalenko et al., 2003). This
region contains a CCHC-type zinc finger motif and a (data not shown), which was also expected to reduce the
conformation exchange rate of the turn. A comparison offlanking proline-rich sequence (388-PPEEPP-393) (Fig-
ures 3A and 3B). Thus, we expected that the CAP-Gly the 15N-NOESY spectra in the presence and absence of
the peptide (Figure 4) revealed several new peaks, whichdomain could recognize the sequence. In addition, we
found another proline-rich sequence just before the re- appeared upon peptide addition.
Ten human proteins, with a total of 17 CAP-Gly domains,gion (369-PPAP-372). In order to assess the interactions
between the CAP-Gly domain and these putative bind- have been found (Figure 5A). The residues conserved in the
human CAP-Gly domains and those showing alterations,ing sites with atomic detail, heteronuclear correlation
experiments were carried out, and the 1H and 15N chemi- such as shifting, disappearing, sharpening, or broaden-
ing, during the perturbation study were compared (Fig-cal shift changes were monitored upon the addition of
the peptides (Figure 3C). The CAP-Gly domain spectra ures 5B–5D). One highly conserved surface (right panels
in Figures 5B–5D) is obviously not involved in the interac-were not affected by the addition of the peptide con-
taining 369-PPAP-372, even at peptide to protein molar tion with the proline-rich peptide. In contrast, the con-
cave surface, which corresponds to the proline-richratios as high as 10 (Figure 3D, upper panel). In contrast,
several crosspeaks changed when the peptide con- peptide binding surface, also shows conservation. The
surface forms a hydrophobic cleft consisting of severaltaining 388-PPEEPP-393 was added to the protein (Fig-
ures 3C and 3D, lower panel). Particularly, the amide hydrophobic residues, such as L505, L510, F522, L536,
F537, and V538. This hydrophobic environment may becrosspeaks of N502 and V538 gradually shifted with the
amount of added peptide, indicating that the exchange a key feature of the proline-rich sequence recognition,
and its conservation among the CAP-Gly domains sug-between the free- and bound forms is fast on the NMR
time scale. Interestingly, the movement of the N485 peak gests that this interaction is common among the CAP-
Gly domains.shows a slow exchange mode. In the absence of the
Structure
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Figure 5. Mapping of the Ligand Binding and Conserved Surfaces on the CAP-Gly Domain
(A) Primary sequence alignment of human CAP-Gly domain-containing proteins. The sequences are CLIP-115 (NCBI Protein Database accession
number BAA22960), CLIP-170 (P30622), TBCB (tubulin folding cofactor B, Q99426), hypo (hypothetical protein, NP_078968), CLIPR-59 (CLIP-
170-related protein, NP_056341), CAP350 (centrosome-associated protein 350, NP_055625), DYNACTIN1 (Q14203), KIF13B (kinesin-like protein
GAKIN, Q9NQT8), TSCE (Homo sapiens tubulin-specific chaperone E, AAP36804), and CYLD (BAA74872). Hydrophobic and aromatic (L, I, M,
V, A, F, W, and Y), basic (K, R, and H), acidic (D and E), proline, and glycine residues are colored differently.
(B) Comparison of the chemical shift mapping results and the conserved residues on the CAP-Gly domains. Perturbed residues are colored
orange, whereas residues that were not observed in the absence of any peptide are yellow. The residues indicated in Figure 4 are colored in
green.
(C) Residue conservation is colored from black (highly conserved) to white (less conserved), as calculated from the sequence alignment of
(A). The putative ligand binding surface shows conservation in the bottom of the hydrophobic cleft (left panel), and the highly conserved
surface is observed on the other side (right panel).
(D) The residues mentioned in (B) and (C) are presented on ribbon models.
Discussion structure of the CAP-Gly domain from nematode hypo-
thetical protein (Li et al., 2002). The region was identified
as a putative TRAF2 binding site in CYLD (457-PVQES-The third CAP-Gly domain of CYLD lacks an  helix in
its amino terminus (Figure 2), in contrast to the crystal 461 [Kovalenko et al., 2003]). The TRAF domain recog-
CAP-Gly Binds to a Proline-Rich Sequence
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Figure 6. The Peptide-Bound Models of the CAP-Gly Domain
(A) The hydrophobic cleft in CAP-Gly, which is formed by L505, F522, L536, F537, and V538, is colored green. Two typical models that docked
the peptide well in the hydrophobic cleft are presented. The backbones of the two peptides are colored in red and blue, respectively. Two
of the proline side chains, corresponding to P7 and P10 in the SQRRSPPEEPPDF sequence, are colored yellow.
(B) Stereoview of the 13-mer peptide-bound model of the CAP-Gly domain. The residues that were expected to be involved in peptide
recognition are presented in green and are labeled on the left. The residues of the peptide are labeled on the right.
nizes the extended structures of diverse receptors (Park in Figure 6B) seems to interact with the aromatic side
chains of F522 and F537 (Figure 6B). This kind of interac-et al., 1999; Ye et al., 1999; McWhirter et al., 1999; Ni et
al., 2000), and therefore it is feasible that the putative tion is often observed in ligand proline recognition in
many proline-rich sequence recognition domains (Mac-TRAF binding site in CYLD is unstructured. The amino
acid sequences of the amino-terminal regions in the ias et al., 2002; Freund et al., 2002). The direction of the
ligand peptide is known to be determined, not by theCAP-Gly domains are not conserved at all (Figure 5A),
and therefore the presence/absence of an  helix there PxxP sequence, but by the flanking charged residue in
the case of the SH3 domain (Cesareni et al., 2002).seems to be one variation in the CAP-Gly family.
The fold of the CAP-Gly domain resembles that of the Although there were only a few NOESY crosspeaks
and we could not assign them exactly (Figure 4), we canSH3 domain (Figure 2), and the CAP-Gly domain binds
to the proline-rich sequence of NEMO/IKK (Figure 3). speculate on the ligand binding by their chemical shift
values and the complex model presented in Figure 6.The SH3 domain, as well as the WW, GYF, and EVH1
domains, is known as a proline-rich ligand binding motif, For example, the amide proton of F537 is located at the
bottom of the hydrophobic cleft, so the new peak aroundand the conserved aromatic residues in the respective
fold families constitute a major interaction site for the 3.8 ppm is probably derived from the 	 proton of one
of the proline residues in the ligand (Figure 6B). Thereproline residues of the ligand (Prehoda et al., 1999;
Freund et al., 2002; Macias et al., 2002). Although L505 is no aromatic side chain around the amide proton of
K541, but new peaks appeared around 
0.1 and 6.7of the third CAP-Gly domain of CYLD is not an aromatic
residue, the corresponding residue is conserved as an ppm. These peaks indicate that the phenylalanine side
chain in the ligand resides around the amide protonaromatic residue among the rest of the proteins in the
family. The position of Y527 is highly conserved as tyro- (Figure 6B), because the chemical shift value of 6.7 ppm
is in good agreement with the 	, , or  proton of asine, except for the first and the second CAP-Gly do-
mains of CYLD, and F537 is also conserved in the family phenylalanine residue, and a chemical shift value of
0.1
ppm is usually observed when a proton stacks against(Figure 5A). Interestingly, these residues are exposed
on the putative ligand binding surface. an aromatic side chain. If these speculations are actually
the case, then these NOEs support the suggestion thatLigand binding to the CAP-Gly domain may not occur
in a simple two-state binding mode, because both slow the peptide direction from left to right in Figure 6A is
more likely than the opposite configuration.and fast modes were observed in the perturbation study
(Figure 3D). One reason is that the mobile turn between Notably, the interaction between the CAP-Gly domain
and the proline-rich peptide seemed to be weak, be- strands 1 and 2 may contribute to the interaction.
Interestingly, the primary sequence of the turn corre- cause a 10-fold molar excess of the peptide to the pro-
tein was required for saturation (the dissociation con-sponds to that of the RT loop in SH3; however, these
regions seem to have different roles in their ligand recog- stant was estimated at 10
4–10
3 M by the NMR titration
study). It is true that signaling interactions are oftennition. The amino acid sequences of the turn region are
variable in the CAP-Gly family (Figure 5A), suggesting intrinsically weak, but we should mention a few possibili-
ties for this weak interaction. We used synthetic, 13that this complex binding mode is not a general feature
among the CAP-Gly family members. amino acid length peptides in this study. There are sev-
eral reports that a neighboring structural motif also con-Two PPEEPP hexapeptide bound models of the CAP-
Gly domain are proposed in Figure 6. These peptides tributes to the interaction by the SH3 and WW domains
(Huang et al., 2000; Ghose et al., 2001; Kami et al.,are positioned in opposite directions, but two proline
residues (colored yellow in Figure 6A) have quite similar 2002). The zinc finger motif is flanked by the proline-
rich sequence of NEMO/IKK, while there are two morelocations. Especially, one proline side chain (proline 7
Structure
1726
phosphate buffer (pH 6.0) containing 100 mM sodium chloride andCAP-Gly domains in CYLD. In cells, CYLD reportedly
1 mM DTT.interacts with both NEMO/IKK and TRAF (Brummel-
kamp et al., 2003; Kovalenko et al., 2003; Trompouki et
NMR Spectroscopy
al., 2003); however, it is unlikely that only CYLD links All NMR spectra were acquired at 25 C on 600 and 800 MHz Bruker
NEMO/IKK to TRAF. Furthermore, regulation by post- Avance NMR spectrometers. The backbone and side chain 1H, 13C,
and 15N resonances of the protein were assigned using the tripletranslational modifications, such as phosphorylation
resonance spectra of HNCA, HN(CO)CA, HNCACB, CBCA(CO)NH,and ubiquitination, should be considered. The carboxyl-
C(CO)NH-TOCSY HBHA(CO)NH, (H)C(CO)NH-TOCSY, 3D HCCH-terminal region of NEMO/IKK is required for IKK activa-
TOCSY, and 3D HCCH-COSY (Clore and Gronenborn, 1994), re-tion (Huang et al., 2002; Makris et al., 2002), and this
corded on a uniformly 15N/13C-labeled protein. NOE-derived distance
region may recruit IKK to the upstream signaling compo- constraints were obtained from 15N- or 13C-edited 3D NOESY spectra.
nents or may regulate specific NEMO modifications to For chemical shift mapping studies, 0.3 mM 15N-labeled construct
was used. 1H, 15N correlation spectra were measured in the absencepermit IKK activation (Huang et al., 2003).
and presence of peptides derived from the human NEMO/IKK se-Most of the CAP-Gly domain-containing proteins are
quence (peptide1: SQAPLPPAPAYLS; peptide2: SQRRSPPEEPPDF)considered as cytoskeleton-associated proteins, and
up to a molar ratio of 1:10.
the domains themselves are responsible for MT binding
(Pierre et al., 1994; Feierbach et al., 1999; Scheel et al., Distance Constraints and Structure Calculations
1999; Radcliffe and Toda, 2000). In the yeast CAP-Gly Interproton distance restraints were obtained from NOESY spectra,
with a mixing time of 80 ms. NOE data were translated to upperdomain of Alf1p, the homolog of mammalian tubulin
limit distance restraints based on 
6 order formulas of the intensityfolding cofactor B, a triple mutation (GKNDG to AENDA,
and the distance. Lower distance bounds were set to 1.8 A˚. Thecorresponding to G516, C517, and G520 in human CYLD)
secondary structured regions were determined by manually as-
disrupts the interaction with -tubulin (Feierbach et al., signing the interproton NOE peaks, and theφ/ angular constraints
1999). These residues are involved in our putative ligand were determined using the program TALOS (Cornilescu et al., 1999)
with a 30 range. Additionally, the side chain angular constraintsbinding surface, and the residue at 517 in CYLD is cyste-
of 1 were determined by a combination of the peak patterns inine, in spite of its high conservation as a lysine residue
HNCOHB and HNHB experiments (Powers et al., 1993).in the CAP-Gly domain family (Figure 5A). The amino
Structures were calculated using a mixed torsion and Cartesian
acid sequences of the CAP-Gly domains in CYLD are angle dynamics simulated annealing protocol with the program CNS
relatively less conserved among the CAP-Gly domains. (Brunger et al., 1998) version 1.1. The starting structure was gener-
If the basic side chain contributes significantly to MT ated as an extended form, and all force constants and molecular
parameters were set to their default values, with the exception ofbinding, then CYLD may not interact with microtubules;
the number of steps, which was increased to 4000 steps for thehowever, -tubulin, as well as Cdc37 and Hsp90, report-
high-temperature annealing stage, 4000 steps for the first slow-cooledly exists in the IKK complex (Chen et al., 2002).
annealing stage, and 6000 steps for the second slow-cool annealing
From this study, we conclude that the CAP-Gly do- stage. Structure modeling, visualization, and superimposition were
main of CYLD associates with the proline-rich sequence done using MOLMOL (Koradi et al., 1996).
of NEMO/IKK. Indeed, the CAP-Gly domain is probably
Model Buildinga proline-rich ligand binding motif.
The initial structure of the Ace-PPEEPP-NMe hexapeptide was con-
structed by homology modeling using the 86-FPEEPP-91 region ofExperimental Procedures
PDB code 1A21. The docking simulation was carried out by Auto-
Dock version 3.0.5 (Morris et al., 1998) with fixing of the φ and 
Immunoprecipitation
angles of the peptide. The search region on the CAP-Gly domain
HeLa cells were transfected with c-myc-tagged human NEMO/IKK
was restricted to one side involving the hydrophobic cleft presented
and Flag-tagged human CYLD (KIAA0849 [Kikuno et al., 2002]) ex-
in Figure 6. Initially, 100 models were outputted, and 11 models
pression vectors. After 24 hr, the cells were lysed in buffer (30 mM
were selected by the final docked energy (less than 
5 kcal/mol)
Tris-HCl [pH 7.4], 150 mM NaCl, 5 mM EDTA, and 1% Triton-X100).
and the structural dissimilarity (more than 3 A˚ root-mean-square-
Cleared cell extracts were incubated with 10 g of anti-Flag M2
deviations against the others). The SQRRSPPEEPPDF peptide model
Affinity Gel (Sigma) and 30g of protein G (SIGMA). For precipitating was created based on the most feasible PPEEPP model, which was
NEMO/IKK, an anti-c-myc antibody was used. selected manually, and the energy was minimized.
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